Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Zanubrutinib in Combination With Rituximab and Venetoclax in Previously Untreated Follicular Lymphoma: An Open Label, Phase 2 Study

NCT06471738 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT06471738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06471738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Zanubrutinib in Combination With Rituximab and Venetoclax in Previously Untreated Follicular Lymphoma: An Open Label, Phase 2 Study
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
July 10, 2024
Completion date
June 1, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ann arbor stage ii follicular lymphoma, ann arbor stage iii follicular lymphoma, ann arbor stage iv follicular lymphoma, grade 1 follicular lymphoma, grade 2 follicular lymphoma, grade 3a follicular lymphoma